Abstract
Although the short-term impact of incident fragility fractures on health-related quality of life (HRQL) of older people has been confirmed, we lack long-term evidence. We explored the impact of incident fragility fractures on HRQL, among people aged 50 years and older, using 10-year prospective data from the Canadian Multicentre Osteoporosis Study (CaMos). This study was based on data from 7753 (2187 men and 5566 women) participants of CaMos. The HRQL, measured through the Health Utility Index (HUI), was captured at baseline and year 10. The incident fragility fractures were recorded over 10 years of follow-up at spine, hip, rib, shoulder, pelvis, or forearm. Multivariable regression analysis was conducted to measure the mean difference, termed as deficit, in the HUI scores for participants with and without fractures. We examined the effects of single or multiple fragility fractures, time (fractures that occurred between year 1 to 5 and 6 to 10) and recovery to the prefracture level. Incident spine and hip fractures were associated with significant deficits (varied from –0.19 to –0.07) on the HUI scores. Hip and spine fractures were associated with negative impact on mobility, self-care, and ambulation. Fractures that occurred closer to the follow-up assessment were associated with significant impact on HRQL compared to fractures occurring a long time before it, except for hip fracture (deficits lasted 5 years or longer). Similarly, multiple hip (–0.14), spine (–0.16), and rib (–0.21) fractures significantly impacted the HRQL of women. Women with a hip fracture never recovered to their prefracture level score (OR = 0.41; 95% confidence interval [CI], 0.19 to 0.98). Our analysis suggests that single and multiple hip fractures as well as multiple spine and rib fractures strongly impact the HRQL of older people over a prolonged period of time.
Original language | English |
---|---|
Pages (from-to) | 838-848 |
Number of pages | 11 |
Journal | Journal of Bone and Mineral Research |
Volume | 34 |
Issue number | 5 |
DOIs | |
Publication status | Published - May 2019 |
Bibliographical note
Funding Information:JDA received grant funding and is on advisory boards and is a speaker for Amgen and Eli Lilly. AP received grant funding and honorarium from Amgen and Eli Lilly. DAH has received research funding from Amgen and Eli Lilly and has received speaking honoraria from Amgen. SMK has received research funding from Amgen and Eli Lilly and is on advisory boards and has received speaker honoraria from Amgen. RJ is a medical advisory board member for Amgen and received speaker honoraria from Amgen and Eli Lilly. OGV, CK, GI, CB, SB, LT, DG, CSK, JCP, SNM, and AMC declare no conflicts of interest for this study.
Funding Information:
No specific funding was received for the current study. SB received Osteoporosis Canada–Tim Murray and Young Investigator Award of the ASBMR to present the abstract at the annual ASBMR meeting 2018. OGV was supported by the 2016 Hamilton Health Sciences postdoctoral fellowship and the 2016 Osteoporosis Canada–CaMos Fellowship award. The Canadian Multi-centre Osteoporosis Study (CaMos) is currently funded by the Canadian Institutes of Health Research (CIHR); and Amgen Canada Inc. Previously CaMos was funded by Merck Canada Inc.; Eli Lilly and Company; Actavis Specialty Pharmaceuticals Co. (formerly Warner Chilcott Canada Co.); and, Hologic Inc.
Publisher Copyright:
© 2019 American Society for Bone and Mineral Research
ASJC Scopus Subject Areas
- Endocrinology, Diabetes and Metabolism
- Orthopedics and Sports Medicine
PubMed: MeSH publication types
- Clinical Trial
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't